

Rochelle Bagatell

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5138495/publications.pdf>

Version: 2024-02-01

99
papers

2,659
citations

218677

26
h-index

197818

49
g-index

99
all docs

99
docs citations

99
times ranked

3697
citing authors

#	ARTICLE	IF	CITATIONS
1	Children's Oncology Group's 2013 blueprint for research: Neuroblastoma. <i>Pediatric Blood and Cancer</i> , 2013, 60, 985-993.	1.5	285
2	Mechanisms of neuroblastoma regression. <i>Nature Reviews Clinical Oncology</i> , 2014, 11, 704-713.	27.6	228
3	Irinotecan+temozolomide with temsirolimus or dinutuximab in children with refractory or relapsed neuroblastoma (COG ANBL1221): an open-label, randomised, phase 2 trial. <i>Lancet Oncology</i> , The, 2017, 18, 946-957.	10.7	205
4	Revised Neuroblastoma Risk Classification System: A Report From the Children's Oncology Group. <i>Journal of Clinical Oncology</i> , 2021, 39, 3229-3241.	1.6	174
5	Phase II Study of Irinotecan and Temozolomide in Children With Relapsed or Refractory Neuroblastoma: A Children's Oncology Group Study. <i>Journal of Clinical Oncology</i> , 2011, 29, 208-213.	1.6	127
6	Historical time to disease progression and progression-free survival in patients with recurrent/refractory neuroblastoma treated in the modern era on Children's Oncology Group early-phase trials. <i>Cancer</i> , 2017, 123, 4914-4923.	4.1	108
7	Irinotecan, Temozolomide, and Dinutuximab With GM-CSF in Children With Refractory or Relapsed Neuroblastoma: A Report From the Children's Oncology Group. <i>Journal of Clinical Oncology</i> , 2020, 38, 2160-2169.	1.6	98
8	Association of <i>MYCN</i> copy number with clinical features, tumor biology, and outcomes in neuroblastoma: A report from the Children's Oncology Group. <i>Cancer</i> , 2017, 123, 4224-4235.	4.1	97
9	Long-Term Follow-up of a Phase III Study of ch14.18 (Dinutuximab) + Cytokine Immunotherapy in Children with High-Risk Neuroblastoma: COG Study ANBL0032. <i>Clinical Cancer Research</i> , 2021, 27, 2179-2189.	7.0	95
10	Phase I trial of temsirolimus in combination with irinotecan and temozolomide in children, adolescents and young adults with relapsed or refractory solid tumors: A children's oncology group study. <i>Pediatric Blood and Cancer</i> , 2014, 61, 833-839.	1.5	87
11	Clinical utility of custom-designed NGS panel testing in pediatric tumors. <i>Genome Medicine</i> , 2019, 11, 32.	8.2	79
12	Neuroblastoma. <i>Pediatric Blood and Cancer</i> , 2021, 68, e28473.	1.5	59
13	Predictors of differential response to induction therapy in high-risk neuroblastoma: A report from the Children's Oncology Group (COG). <i>European Journal of Cancer</i> , 2019, 112, 66-79.	2.8	49
14	Accuracy of Adverse Event Ascertainment in Clinical Trials for Pediatric Acute Myeloid Leukemia. <i>Journal of Clinical Oncology</i> , 2016, 34, 1537-1543.	1.6	47
15	Genetic discoveries and treatment advances in neuroblastoma. <i>Current Opinion in Pediatrics</i> , 2016, 28, 19-25.	2.0	44
16	The challenge of defining "ultra-high-risk" neuroblastoma. <i>Pediatric Blood and Cancer</i> , 2019, 66, e27556.	1.5	43
17	Development and Clinical Validation of a Large Fusion Gene Panel for Pediatric Cancers. <i>Journal of Molecular Diagnostics</i> , 2019, 21, 873-883.	2.8	41
18	Assessment of Primary Site Response in Children With High-Risk Neuroblastoma: An International Multicenter Study. <i>Journal of Clinical Oncology</i> , 2016, 34, 740-746.	1.6	37

#	ARTICLE	IF	CITATIONS
19	Unrealistic parental expectations for cure in poor-prognosis childhood cancer. <i>Cancer</i> , 2020, 126, 416-424.	4.1	34
20	Poverty and Targeted Immunotherapy: Survival in Children's Oncology Group Clinical Trials for High-Risk Neuroblastoma. <i>Journal of the National Cancer Institute</i> , 2021, 113, 282-291.	6.3	33
21	Diagnosis of Beckwith-Wiedemann syndrome in children presenting with Wilms tumor. <i>Pediatric Blood and Cancer</i> , 2018, 65, e27296.	1.5	32
22	Using electronic medical record data to report laboratory adverse events. <i>British Journal of Haematology</i> , 2017, 177, 283-286.	2.5	31
23	Likelihood of Bone Recurrence in Prior Sites of Metastasis in Patients With High-Risk Neuroblastoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014, 89, 839-845.	0.8	30
24	Vincristine, irinotecan, and temozolomide in children and adolescents with relapsed rhabdomyosarcoma. <i>Pediatric Blood and Cancer</i> , 2018, 65, e26728.	1.5	30
25	The ganglioside G _{D2} as a circulating tumor biomarker for neuroblastoma. <i>Pediatric Blood and Cancer</i> , 2020, 67, e28031.	1.5	30
26	The role of acuity of illness at presentation in early mortality in black children with acute myeloid leukemia. <i>American Journal of Hematology</i> , 2017, 92, 141-148.	4.1	29
27	Efficacy of crizotinib in children with relapsed/refractory ALK-driven tumors including anaplastic large cell lymphoma and neuroblastoma: A Children's Oncology Group phase I consortium study. <i>Journal of Clinical Oncology</i> , 2012, 30, 9500-9500.	1.6	29
28	Pantoprazole, an Inhibitor of the Organic Cation Transporter 2, Does Not Ameliorate Cisplatin-Related Ototoxicity or Nephrotoxicity in Children and Adolescents with Newly Diagnosed Osteosarcoma Treated with Methotrexate, Doxorubicin, and Cisplatin. <i>Oncologist</i> , 2018, 23, 762-e79.	3.7	28
29	Racial and Ethnic Differences in Communication and Care for Children With Advanced Cancer. <i>Journal of Pain and Symptom Management</i> , 2020, 60, 782-789.	1.2	27
30	Advances in neuroblastoma therapy. <i>Current Opinion in Pediatrics</i> , 2019, 31, 14-20.	2.0	25
31	Association of Weekend Admission With Hospital Length of Stay, Time to Chemotherapy, and Risk for Respiratory Failure in Pediatric Patients With Newly Diagnosed Leukemia at Freestanding US Children's Hospitals. <i>JAMA Pediatrics</i> , 2014, 168, 925.	6.2	24
32	Suspected posaconazole toxicity in a pediatric oncology patient. <i>Pediatric Blood and Cancer</i> , 2015, 62, 1682-1682.	1.5	24
33	Proton therapy for pediatric head and neck malignancies. <i>Pediatric Blood and Cancer</i> , 2018, 65, e26858.	1.5	24
34	Comparison of in-patient costs for children treated on the AAML0531 clinical trial: A report from the Children's Oncology Group. <i>Pediatric Blood and Cancer</i> , 2015, 62, 1775-1781.	1.5	21
35	Patterns of Relapse in High-Risk Neuroblastoma Patients Treated With and Without Total Body Irradiation. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 97, 270-277.	0.8	20
36	Outcomes After Proton Therapy for Treatment of Pediatric High-Risk Neuroblastoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 104, 401-408.	0.8	19

#	ARTICLE	IF	CITATIONS
37	A comparison of resource utilization following chemotherapy for acute myeloid leukemia in children discharged versus children that remain hospitalized during neutropenia. <i>Cancer Medicine</i> , 2015, 4, 1356-1364.	2.8	17
38	A safety and feasibility trial of ¹³¹ I-MIBG in newly diagnosed high-risk neuroblastoma: A Children's Oncology Group study. <i>Pediatric Blood and Cancer</i> , 2021, 68, e29117.	1.5	17
39	Merging Children's Oncology Group Data with an External Administrative Database Using Indirect Patient Identifiers: A Report from the Children's Oncology Group. <i>PLoS ONE</i> , 2015, 10, e0143480.	2.5	16
40	Establishing a high-risk neuroblastoma cohort using the pediatric health information system database. <i>Pediatric Blood and Cancer</i> , 2014, 61, 1129-1131.	1.5	15
41	Myeloablative Busulfan/Melphalan Consolidation following Induction Chemotherapy for Patients with Newly Diagnosed High-Risk Neuroblastoma: Children's Oncology Group Trial ANBL12P1. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 490.e1-490.e8.	1.2	14
42	Segmental Chromosomal Aberrations in Localized Neuroblastoma Can be Detected in Formalin-Fixed Paraffin-Embedded Tissue Samples and Are Associated With Recurrence. <i>Pediatric Blood and Cancer</i> , 2016, 63, 1019-1023.	1.5	13
43	Comparison of administrative/billing data to expected protocol-mandated chemotherapy exposure in children with acute myeloid leukemia: A report from the Children's Oncology Group. <i>Pediatric Blood and Cancer</i> , 2015, 62, 1184-1189.	1.5	12
44	Sclerosing Epithelioid Fibrosarcoma of the Bone With Rare EWSR1-CREB3L3 Translocation Driving Upregulation of the PI3K/mTOR Signaling Pathway. <i>Pediatric and Developmental Pathology</i> , 2019, 22, 594-598.	1.0	12
45	Outcomes among pediatric patients with cancer who are treated on trial versus off trial: A matched cohort study. <i>Cancer</i> , 2020, 126, 3471-3482.	4.1	12
46	Volume-Outcome Relationships in Pediatric Acute Lymphoblastic Leukemia: Association Between Hospital Pediatric and Pediatric Oncology Volume With Mortality and Intensive Care Resources During Initial Therapy. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2016, 16, 404-410.e1.	0.4	11
47	Outcomes Following GD2-Directed Postconsolidation Therapy for Neuroblastoma After Cessation of Random Assignment on ANBL0032: A Report From the Children's Oncology Group. <i>Journal of Clinical Oncology</i> , 2022, 40, 4107-4118.	1.6	11
48	Hospital Variation in Intensive Care Resource Utilization and Mortality in Newly Diagnosed Pediatric Leukemia*. <i>Pediatric Critical Care Medicine</i> , 2018, 19, e312-e320.	0.5	10
49	Resource Utilization and Toxicities After Carboplatin/Etoposide/Melphalan and Busulfan/Melphalan for Autologous Stem Cell Rescue in High-Risk Neuroblastoma Using a National Administrative Database. <i>Pediatric Blood and Cancer</i> , 2016, 63, 901-907.	1.5	8
50	Low rates of pregnancy screening in adolescents before teratogenic exposures in a national sample of children's hospitals. <i>Cancer</i> , 2016, 122, 3394-3400.	4.1	8
51	Germline Sequencing Improves Tumor-Only Sequencing Interpretation in a Precision Genomic Study of Patients With Pediatric Solid Tumor. <i>JCO Precision Oncology</i> , 2021, 5, 1840-1852.	3.0	8
52	A pilot induction regimen incorporating dinutuximab and sargramostim for the treatment of newly diagnosed high-risk neuroblastoma: A report from the Children's Oncology Group.. <i>Journal of Clinical Oncology</i> , 2022, 40, 10003-10003.	1.6	6
53	Bortezomib Inpatient Prescribing Practices in Free-Standing Children's Hospitals in the United States. <i>PLoS ONE</i> , 2016, 11, e0151362.	2.5	5
54	Efficacy of post-induction therapy for high-risk neuroblastoma patients with end-induction residual disease. <i>Cancer</i> , 2022, 128, 2967-2977.	4.1	5

#	ARTICLE	IF	CITATIONS
55	A Rapid Progression of Disease After Surgical Excision of a Malignant Rhabdoid Tumor of the Bladder. <i>Urology</i> , 2015, 85, 664-666.	1.0	4
56	Early discharge as a mediator of greater ICU-level care requirements in patients not enrolled on the AAML0531 clinical trial: a Children's Oncology Group report. <i>Cancer Medicine</i> , 2016, 5, 2412-2416.	2.8	4
57	The Beginning of the End of Package Deal Therapy for Patients With High-Risk Neuroblastoma?. <i>Journal of Clinical Oncology</i> , 2016, 34, 2437-2439.	1.6	4
58	Center-level variation in accuracy of adverse event reporting in a clinical trial for pediatric acute myeloid leukemia: a report from the Children's Oncology Group. <i>Haematologica</i> , 2017, 102, e340-e343.	3.5	4
59	Resource utilization and toxicities after single versus tandem autologous stem cell rescue in high-risk neuroblastoma using a national administrative database. <i>Pediatric Blood and Cancer</i> , 2018, 65, e27372.	1.5	4
60	Improving Outcomes in Children With High-Risk Neuroblastoma: The Role of Randomized Trials. <i>Journal of Clinical Oncology</i> , 2021, 39, 2525-2527.	1.6	4
61	Phase II randomized trial of irinotecan/temozolomide (I/T) with temsirolimus (TEM) or dinutuximab plus granulocyte colony stimulating factor (DIN/GMCSF) in children with refractory or relapsed neuroblastoma: A report from the Children's Oncology Group (COG).. <i>Journal of Clinical Oncology</i> , 2016, 34, 10502-10502.	1.6	4
62	Tandem Transplant for High-Risk Neuroblastoma. <i>JAMA - Journal of the American Medical Association</i> , 2019, 322, 729.	7.4	3
63	Role of Metastatic Site Irradiation in Pediatric Patients With Metastatic Ewing Sarcoma. <i>Journal of Pediatric Hematology/Oncology</i> , 2020, 42, e305-e309.	0.6	3
64	A pharmacologically-based approach to high dose methotrexate administration to investigate nephrotoxicity and acute kidney injury biomarkers in children and adolescents with newly diagnosed osteosarcoma. <i>Cancer Chemotherapy and Pharmacology</i> , 2021, 87, 807-815.	2.3	3
65	Phase 1 study of sorafenib and irinotecan in pediatric patients with relapsed or refractory solid tumors. <i>Pediatric Blood and Cancer</i> , 2021, 68, e29282.	1.5	3
66	Historical gold standard for time-to-progression (TTP) and progression-free survival (PFS) from relapsed/refractory neuroblastoma modern era (2002-2014) patients.. <i>Journal of Clinical Oncology</i> , 2014, 32, 10034-10034.	1.6	3
67	Evaluation of resources used during care of children with high-risk neuroblastoma (HR NBL) via merging of cooperative group trial data and administrative data.. <i>Journal of Clinical Oncology</i> , 2014, 32, 10069-10069.	1.6	3
68	Myeloablative busulfan/melphalan (BuMel) consolidation following induction chemotherapy for patients with high-risk neuroblastoma: A Children's Oncology Group (COG) study.. <i>Journal of Clinical Oncology</i> , 2016, 34, 10528-10528.	1.6	3
69	Phase II trial of irinotecan/temozolomide/dinutuximab/granulocyte macrophage colony stimulating factor (I/T/DIN/GMCSF) in children with relapsed/refractory neuroblastoma (NBL): A report from the Children's Oncology Group (COG).. <i>Journal of Clinical Oncology</i> , 2018, 36, 10508-10508.	1.6	3
70	Clinical impact of molecular tumor profiling in pediatric, adolescent, and young adult patients with extra-cranial solid malignancies: An interim report from the GAIN/iCat2 study.. <i>Journal of Clinical Oncology</i> , 2021, 39, 10005-10005.	1.6	2
71	G _{D2} as a circulating tumor biomarker (CTB) for neuroblastoma (NBL).. <i>Journal of Clinical Oncology</i> , 2018, 36, 10538-10538.	1.6	2
72	Refining megatherapy, improving outcome in neuroblastoma. <i>Lancet Oncology</i> , The, 2017, 18, 423-424.	10.7	1

#	ARTICLE	IF	CITATIONS
73	Phase I trial of temsirolimus (TEM), irinotecan (IRN), and temozolomide (TMZ) in children with refractory solid tumors: AA Children's Oncology Group study.. Journal of Clinical Oncology, 2012, 30, 9540-9540.	1.6	1
74	Phase 1 study of sorafenib and irinotecan in pediatric patients with relapsed or refractory solid tumors.. Journal of Clinical Oncology, 2014, 32, 10052-10052.	1.6	1
75	Poverty and survival in targeted immunotherapy clinical trials.. Journal of Clinical Oncology, 2019, 37, 10034-10034.	1.6	1
76	Variability in Antifungal Use for Pediatric Acute Myeloid Leukemia At Children's Hospitals Across the United States. Blood, 2012, 120, 4278-4278.	1.4	1
77	Treatment Toxicity and Supportive Care Utilization in Children with Down Syndrome and Acute Lymphoid Leukemia at Free-Standing Pediatric Hospitals in the United States. Blood, 2014, 124, 553-553.	1.4	1
78	A revised Children's Oncology Group (COG) neuroblastoma risk classification system: Report from the COG biology study ANBL00B1.. Journal of Clinical Oncology, 2019, 37, 10012-10012.	1.6	1
79	Clinical significance of serial tumor next generation sequencing (NGS) in 155 pediatric cancer patients.. Journal of Clinical Oncology, 2020, 38, e13666-e13666.	1.6	1
80	More Than Meets the Eye? A Cautionary Tale of Malignant Ectomesenchymoma Treated as Low-risk Orbital Rhabdomyosarcoma. Journal of Pediatric Hematology/Oncology, 2021, 43, e854-e858.	0.6	1
81	Progression-free survival and patterns of response in patients with high-risk neuroblastoma (HR-NB) treated with irinotecan/temozolomide/dinutuximab/granulocyte-macrophage colony-stimulating factor (I/T/DIN/GM-CSFS) chemoimmunotherapy.. Journal of Clinical Oncology, 2022, 40, 10025-10025.	1.6	1
82	Mortality and Resource Utilization in Children with De Novo Acute Myeloid Leukemia Treated with Chemotherapy and Gemtuzumab Ozogamicin in the United States. Blood, 2012, 120, 4283-4283.	1.4	0
83	Impact of weekend admission on hospital length of stay and organ failure in pediatric leukemia patients at free-standing U.S. children's hospitals.. Journal of Clinical Oncology, 2014, 32, 6598-6598.	1.6	0
84	Standardized costs and outcome in children treated with gemtuzumab on the AAML0531 trial: A report from the Children's Oncology Group.. Journal of Clinical Oncology, 2014, 32, 7086-7086.	1.6	0
85	Pediatric Hospital Volume and Induction Mortality in Pediatric Acute Lymphoblastic Leukemia (ALL). Blood, 2014, 124, 2653-2653.	1.4	0
86	Resource Utilization and Cost Analysis By Treatment Arm on the Children's Oncology Group AALL0232 Phase 3 High-Risk B-Precursor Acute Lymphoblastic Leukemia Trial: A Report from the Children's Oncology Group. Blood, 2014, 124, 210-210.	1.4	0
87	Resource utilization (RU) and toxicities after carboplatin/etoposide/melphalan (CEM) and busulfan/melphalan (BuMel) for autologous stem cell rescue (ASCR) in high-risk neuroblastoma (HRNB).. Journal of Clinical Oncology, 2015, 33, e21009-e21009.	1.6	0
88	Racial Disparities in Pediatric Acute Myeloid Leukemia during Induction. Blood, 2015, 126, 530-530.	1.4	0
89	Phase II study of alisertib, irinotecan, and temozolomide in children with relapsed and refractory neuroblastoma: A report from the New Approaches to Neuroblastoma Therapy (NANT) consortium.. Journal of Clinical Oncology, 2016, 34, 10556-10556.	1.6	0
90	Effect of infusion duration on high-dose methotrexate (HDMTX) acute kidney injury (AKI).. Journal of Clinical Oncology, 2017, 35, e22013-e22013.	1.6	0

#	ARTICLE	IF	CITATIONS
91	Predictors of differential response to induction chemotherapy in high-risk neuroblastoma: A report from the Children's Oncology Group (COG).. Journal of Clinical Oncology, 2018, 36, 10532-10532.	1.6	0
92	Using administrative laboratory result data to describe adverse events.. Journal of Clinical Oncology, 2018, 36, e18698-e18698.	1.6	0
93	Outcome in patients with refractory high-risk neuroblastoma.. Journal of Clinical Oncology, 2020, 38, 10537-10537.	1.6	0
94	Trends in conditional survival and predictors of late death in neuroblastoma.. Journal of Clinical Oncology, 2020, 38, 10533-10533.	1.6	0
95	Outcomes and toxicities in patients (pts) non-randomly assigned to immunotherapy Children's Oncology Group (COG) ANBL0032.. Journal of Clinical Oncology, 2020, 38, 10523-10523.	1.6	0
96	Impact of diagnostic and end-of-induction Curie scores in tandem autologous hematopoietic cell transplant for patients with high-risk neuroblastoma: A report from the Children's Oncology Group.. Journal of Clinical Oncology, 2022, 40, 10027-10027.	1.6	0
97	Predictors of differential outcomes according to response to induction chemotherapy in high-risk neuroblastoma.. Journal of Clinical Oncology, 2022, 40, 10032-10032.	1.6	0
98	Racial, ethnic, and socioeconomic survival disparities among children with high-risk neuroblastoma treated on upfront Children's Oncology Group clinical trials.. Journal of Clinical Oncology, 2022, 40, 10005-10005.	1.6	0
99	Patterns of relapse after immunotherapy in patients with high-risk neuroblastoma.. Journal of Clinical Oncology, 2022, 40, 10043-10043.	1.6	0